Fungal diseases are classified as superficial, subcutaneous, and systemic according to the level of infection. Of these, superficial fungal infections are the most common in clinical dermatology. Superficial fungal infections are confined to the cuticle and appendages of the skin. Superficial fungal infections are superficial fungal infections caused by ringworm invading the keratinized tissues of humans and animals, involving the epidermis, hair, and nails, and are caused by Microsporum, Trichophyton, Candida, and Malassezia infections. Superficial fungal diseases are subdivided by site into ringworm of the body, ringworm of the femur, ringworm of the feet, ringworm of the hands, ringworm of the nails, and ringworm of the body.

Many scientists seek to establish experimental animal models to elucidate the pathogenesis of human dermatophytosis and to assess drug efficacy. Ace Therapeutics offers customized animal models of superficial fungal infections, including guinea pig models and rabbit models. These models are useful for further investigation of fungal pathogenesis, host antifungal immune response, and development of antifungal compounds.

Customized Service Options for Superficial Skin Fungal Infection Animal Models

• Guinea pig model of superficial dermal fungal infection
• Rabbit model of superficial dermal fungal infection

[Model animals] Guinea pigs often develop spontaneous dermatophytosis due to their susceptibility to ringworm, making them a more desirable animal model for studying ringworm disease. There is also a dermatophyte model of ringworm in rabbits.

[Modeling mechanism] We use strains from the standard strains preserved and confirmed by medical fungal preservation units or clinical isolates identified by them. We will do qualitative and quantitative in vitro antifungal efficacy tests before the experiment to determine the lowest drug concentration that can inhibit and kill the fungal growth.

[Molding method] Topical or oral administration. Usually, the skin on the back side of the trunk is debrided with sandpaper and inoculated with 1×107 fungal cells, or the amount of infection is determined in advance.

[Model characteristics] The disease usually appears within 5-6 days of infection. After topical or oral administration, the efficacy is judged by changes in skin lesions, fungal microscopy, and culture results. The model has a high degree of conformity with the clinic.

[Model evaluation and application] The model is mainly used for in vivo evaluation of the efficacy of antifungal drugs administered topically or systemically.

• Parasitology discovery and pre-research service
• Parasitology metabolism research service
• Parasitology target and structure function research
• Parasitology effectiveness evaluation service
• Parasitology safety evaluation service
• Parasitology pharmacological research service